Stockscreener 앱 받기
2.24
6.70%
0.15
전일 마감가:
$2.09
열려 있는:
$2.1
하루 거래량:
178.16K
Relative Volume:
0.73
시가총액:
$55.44M
수익:
$210.70K
순이익/손실:
$-21.37M
주가수익비율:
-2.0364
EPS:
-1.1
순현금흐름:
$-21.10M
1주 성능:
+0.00%
1개월 성능:
+2.29%
6개월 성능:
+100.90%
1년 성능:
-42.38%
1일 변동 폭
$2.045
$2.23
1주일 범위
$1.96
$2.30
52주 변동 폭
$0.89
$5.33
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
GANX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.23 | 55.44M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.98 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
682.32 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.04 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
121.34 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - PR Newswire
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - Yahoo Finance
Perrigo cut to Hold at Argus on topline risks - MSN
Regions Financial Q4 2024 Earnings Preview - MSN
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - MSN
Gain Therapeutics regains compliance with Nasdaq listing By Investing.com - Investing.com South Africa
Gain Therapeutics regains compliance with Nasdaq listing - Investing.com India
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
Geode Capital Management LLC Has $484,000 Stock Holdings in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Coinbase Global Inc (COIN) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Best Momentum Stocks to Buy for January 9th - Yahoo Finance
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - The Manila Times
Gain Therapeutics Forms Elite Advisory Board to Accelerate Parkinson's Drug Development - StockTitan
Gain Therapeutics (GANX) Shares Rise In After-Hour Trading - Stocks Telegraph
Gain Therapeutics Appoints New CEO Amidst Clinical Progress - TipRanks
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer - Marketscreener.com
Gain Therapeutics appoints new CEO and finance SVP - Investing.com
Gain Therapeutics Appoints Gene Mack as CEO - citybiz
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director - The Manila Times
Gain Therapeutics Names Gene Mack as CEO, Advancing Parkinson's Disease Drug Development - StockTitan
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - MSN
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Tarsus PharmaceuticalEye Care Therapeutics - TradingView
Gold just saw its biggest yearly gain since 2010 — here's why Wall Street says prices will go even higher - Yahoo Finance
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM - Yahoo Finance
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Roth Mkm - Defense World
Gain Therapeutics (NASDAQ:GANX) Initiates Phase 1b Clinical Trial for GT-02287 in Australia - Defense World
S&P 500, Nasdaq gain in choppy trading as most megacaps move higher - MSN
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Benzinga
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? - MSN
Gain Therapeutics Advances GT-02287 into Phase 1b Trial - TipRanks
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - The Manila Times
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with - The Bakersfield Californian
Gain Therapeutics Advances Parkinson's Treatment: Phase 1b Trial Approved After Promising Early Results - StockTitan
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.45%
5.38%
자본화:
|
볼륨(24시간):